tiprankstipranks
Trending News
More News >
Anebulo Pharmaceuticals, Inc. (ANEB)
:ANEB
Advertisement

Anebulo Pharmaceuticals (ANEB) Price & Analysis

Compare
34 Followers

ANEB Stock Chart & Stats

$2.66
-$0.06(-3.96%)
At close: 4:00 PM EST
$2.66
-$0.06(-3.96%)

Bulls Say, Bears Say

Bulls Say
Corporate StrategyBoard approves plan to go private at a 91% premium to previous close.
Bears Say
Stock PriceThe upside potential is limited as the shares approach the transaction price and exceed the 12-month price target.
Stock RatingStock rating downgraded to Hold.

Anebulo Pharmaceuticals News

ANEB FAQ

What was Anebulo Pharmaceuticals, Inc.’s price range in the past 12 months?
Anebulo Pharmaceuticals, Inc. lowest stock price was $0.80 and its highest was $3.42 in the past 12 months.
    What is Anebulo Pharmaceuticals, Inc.’s market cap?
    Anebulo Pharmaceuticals, Inc.’s market cap is $104.36M.
      When is Anebulo Pharmaceuticals, Inc.’s upcoming earnings report date?
      Anebulo Pharmaceuticals, Inc.’s upcoming earnings report date is Feb 06, 2026 which is in 90 days.
        How were Anebulo Pharmaceuticals, Inc.’s earnings last quarter?
        Currently, no data Available
        Is Anebulo Pharmaceuticals, Inc. overvalued?
        According to Wall Street analysts Anebulo Pharmaceuticals, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Anebulo Pharmaceuticals, Inc. pay dividends?
          Anebulo Pharmaceuticals, Inc. does not currently pay dividends.
          What is Anebulo Pharmaceuticals, Inc.’s EPS estimate?
          Anebulo Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Anebulo Pharmaceuticals, Inc. have?
          Anebulo Pharmaceuticals, Inc. has 41,084,732 shares outstanding.
            What happened to Anebulo Pharmaceuticals, Inc.’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Anebulo Pharmaceuticals, Inc.?
            Currently, no hedge funds are holding shares in ANEB

            Anebulo Pharmaceuticals Stock Smart Score

            4
            Neutral
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Technicals

            SMA
            Positive
            20 days / 200 days
            Momentum
            33.68%
            12-Months-Change

            Fundamentals

            Return on Equity
            -109.69%
            Trailing 12-Months
            Asset Growth
            198.19%
            Trailing 12-Months

            Company Description

            Anebulo Pharmaceuticals, Inc.

            Anebulo Pharmaceuticals (ANEB) is a clinical-stage biotechnology company focused on developing novel treatments for patients suffering from cannabinoid overdose and substance addiction. The company primarily operates within the pharmaceutical and biotechnology sectors, targeting unmet medical needs related to the growing marijuana and cannabinoid markets. Anebulo's lead product candidate, ANEB-001, is an orally administered small molecule designed to treat acute cannabinoid intoxication.

            Anebulo Pharmaceuticals (ANEB) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            VistaGen Therapeutics
            Beyondspring
            Surrozen
            Context Therapeutics
            Alto Neuroscience, Inc.

            Ownership Overview

            78.18%0.58%0.85%20.00%
            78.18% Insiders
            0.85% Other Institutional Investors
            20.00% Public Companies and
            Individual Investors

            Options Prices

            Currently, No data available
            ---
            Popular Stocks
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis